Alpine Immune Sciences Inc.: Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc's - - Ongoing phase 1 study demonstrates highly encouraging preliminary
Source: finanznachrichten.de
